Maxim Group Cuts Silexion Therapeutics (NASDAQ:SLXN) Price Target to $5.00

Silexion Therapeutics (NASDAQ:SLXN) had its price target lowered by Maxim Group from $9.00 to $5.00 in a report issued on Thursday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Silexion Therapeutics Stock Performance

NASDAQ:SLXN opened at $1.11 on Thursday. Silexion Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $41.85. The firm has a 50-day simple moving average of $1.25 and a two-hundred day simple moving average of $3.02.

Institutional Trading of Silexion Therapeutics

A hedge fund recently bought a new stake in Silexion Therapeutics stock. Wildcat Capital Management LLC acquired a new stake in shares of Silexion Therapeutics Corp (NASDAQ:SLXN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,020,852 shares of the company’s stock, valued at approximately $536,000. Silexion Therapeutics makes up 0.3% of Wildcat Capital Management LLC’s investment portfolio, making the stock its 7th biggest holding. Wildcat Capital Management LLC owned 7.38% of Silexion Therapeutics at the end of the most recent quarter. 10.95% of the stock is owned by institutional investors.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.